Ovarian Cancer, Epithelial
Oncology·MeSH: Carcinoma, Ovarian Epithelial
Prevalence
24.0 / 100K
Incidence
10.6 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| NX-1607 | Nurix Therapeutics, Inc. (NRIX) |
Frequently asked questions
How many drugs are in development for Ovarian Cancer, Epithelial?
BioSniper tracks 1 drug in development for Ovarian Cancer, Epithelial across 1 company.
How many clinical trials target Ovarian Cancer, Epithelial?
There are 1 clinical trial targeting Ovarian Cancer, Epithelial tracked by BioSniper.
What is the prevalence of Ovarian Cancer, Epithelial?
The estimated prevalence of Ovarian Cancer, Epithelial is approximately 24.0 per 100,000 population.
Deep-dive into Ovarian Cancer, Epithelial
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis